ebola
viru
diseas
sever
diseas
caus
highli
pathogen
ebolavirus
although
show
high
mortal
rate
human
current
licens
therapeut
recent
epidem
west
africa
demonstr
administr
antimalari
medic
contain
amodiaquin
significantli
lower
mortal
rate
patient
infect
viru
order
improv
antivir
activ
seri
amodiaquin
deriv
synthes
test
ebola
viru
infect
found
multipl
compound
potent
amodiaquin
structureact
relationship
analysi
reveal
two
independ
part
alkyl
chain
extend
aminomethyl
group
halogen
bond
quinolin
ring
key
enhanc
antivir
potenc
without
increas
toxic
modif
combin
antivir
efficaci
could
improv
select
index
higher
amodiaquin
mechanist
evalu
demonstr
potent
deriv
block
host
cell
entri
ebola
viru
like
parent
amodiaquin
taken
togeth
work
identifi
novel
potent
amodiaquin
deriv
aid
develop
effect
antivir
therapeut
ebola
viru
ebov
caus
sever
diseas
high
mortal
rate
human
basel
et
al
diseas
progress
rapidli
easili
transmit
direct
contact
patient
contamin
materi
sinc
discov
ebov
caus
sporad
outbreak
increas
frequenc
affect
area
epidem
west
africa
result
infect
case
death
multipl
case
found
outsid
endem
region
lo
et
al
creat
signific
public
health
threat
around
world
although
sever
antivir
candid
clinic
test
none
shown
clear
signific
benefit
patient
van
griensven
et
al
sissoko
et
al
dun
et
al
b
prevail
ii
write
group
emphas
need
develop
effect
antivir
therapeut
one
approach
therapeut
develop
repurpos
exist
drug
mercorelli
et
al
inde
sever
studi
identifi
multipl
approv
drug
show
antiebov
activ
vitro
vivo
madrid
et
al
johansen
et
al
sakurai
et
al
johansen
et
al
madrid
et
al
repurpos
take
advantag
known
drug
kinet
formul
knowledg
chemic
featur
appli
novel
treatment
purpos
function
compound
could
potenti
rel
simpl
track
clinic
strittmatt
unfortun
take
approach
produc
potent
candid
offlabel
use
clinic
effect
antivir
dosag
much
higher
clinic
use
bixler
et
al
outcom
understand
given
clinic
approv
small
molecul
experienc
extens
structureact
relationship
sar
analys
focus
specif
diseas
indic
develop
approach
take
advantag
establish
synthesi
chemistri
formul
clinic
knowledg
evalu
detail
sar
new
indic
use
initi
hit
start
point
recent
screen
effort
use
clinic
use
small
molecul
identifi
antimalari
compound
potent
ebov
inhibitor
madrid
et
al
madrid
et
al
ekin
et
al
one
amodiaquin
clinic
use
oral
antimalari
medic
year
world
health
organ
list
essenti
medicin
wide
avail
africa
low
cost
world
health
organ
cytochrom
enzym
desethylamodiaquin
long
halflif
day
backman
et
al
previou
report
show
antiebov
activ
amodiaquin
desethylamodiaquin
cell
cultur
madrid
et
al
zilbermintz
et
al
suggest
potenti
longlast
antivir
activ
human
although
detail
mechan
action
fulli
understood
viru
entri
cell
appear
inhibit
interestingli
epidem
ebov
amodiaquin
combin
artemisinin
deriv
prescrib
malaria
patient
endem
region
later
analysi
reveal
among
peopl
infect
ebola
viru
receiv
amodiaquin
show
significantli
decreas
case
mortal
vs
compar
receiv
nonaminoquinolinebas
antimalari
drug
artemisinin
deriv
treatment
gignoux
et
al
suggest
amodiaquin
may
provid
clinic
benefit
ebola
viru
diseas
patient
requir
substanti
improv
potenc
use
studi
synthes
mechanist
evalu
seri
exist
novel
amodiaquin
deriv
defin
sar
antiebov
activ
aim
identifi
compound
low
toxic
improv
potenc
ebov
infect
cell
gift
dr
stanley
lemon
univers
north
carolina
nc
cell
cdc
atlanta
ga
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
penicillinstreptomycin
solut
cell
purchas
life
technolog
cultur
dmem
ngml
nuclear
stain
dye
purchas
life
technolog
includ
amodiaquin
newli
synthes
tokushima
bunri
univers
synthet
method
describ
patent
applic
puriti
compound
analyz
ident
confirm
h
c
nuclear
magnet
reson
nmr
highresolut
mass
spectrometri
data
shown
compound
dissolv
mm
dmso
store
use
recombin
ebov
encod
gfp
report
gene
ebovgfp
provid
dr
heinz
feldmann
rocki
mountain
laboratori
nation
institut
health
hamilton
mt
viru
cultiv
cell
infect
multipl
infect
moi
approxim
cultur
supernat
collect
day
clarifi
centrifug
min
viru
concentr
ultracentrifug
h
pellet
sucros
cushion
resuspend
phosphat
buffer
salin
pb
viru
titer
determin
serial
dilut
cell
hincub
cell
fix
formalin
h
wash
pb
stain
hoechst
dye
imag
nikon
ti
eclips
invert
microscop
len
count
cell
nuclei
gfpposit
foci
perform
use
cell
profil
imag
analysi
softwar
broad
institut
mit
boston
custom
analysi
pipelin
avail
request
infect
assay
cell
seed
well
plate
incub
overnight
cell
pretreat
least
h
compound
dilut
across
serial
dilut
seri
challeng
ebovgfp
moi
h
time
correspond
approxim
one
round
replic
accumul
suffici
gfp
signal
detect
infect
cell
cell
fix
analyz
describ
experi
replic
compet
ebola
viru
perform
biosafeti
level
laboratori
texa
biomed
research
institut
drug
cytotox
measur
use
celltiterglo
luminesc
cell
viabil
assay
promega
madison
wi
follow
manufactur
protocol
cell
seed
white
wall
well
plate
corn
lowel
incub
compound
h
assay
buffer
ad
cultur
plate
incub
addit
min
room
temperatur
luminesc
measur
use
plate
luminomet
promega
madison
wi
evalu
compound
inhibit
glycoprotein
gp
function
control
viru
entri
cell
gppseudotyp
recombin
vesicular
stomat
virus
vsv
made
g
gene
replac
luciferas
report
gene
gp
suppli
exogen
pseudotyp
ebov
marburg
viru
gp
respect
gener
start
marv
gp
suppli
transfect
cell
plasmid
pmarv
musok
gp
nonspecif
carrier
plasmid
use
calcium
phosphat
method
cm
dish
twenti
four
hour
transfect
cell
challeng
left
overnight
supernat
harvest
h
challeng
store
use
product
cell
transfect
pebov
mayinga
gp
plasmid
carrier
cell
twenti
four
hour
transfect
cell
challeng
overnight
wash
twice
pb
latter
viru
use
instead
marv
gp
labil
vsvg
readili
carri
lower
titer
ebovgp
bear
pseudotyp
supernat
harvest
h
infect
store
use
control
carryov
inocul
parent
viru
cell
transfect
plasmid
express
alon
challeng
parent
viru
stock
cultur
supernat
collect
test
activ
viru
titer
determin
serial
dilut
cell
luciferas
activ
measur
h
postinfect
cell
plate
white
wall
plate
corn
lowel
incub
compound
serial
dilut
h
ad
cell
challeng
viru
presenc
compound
h
medium
replac
luciferas
assay
buffer
mm
tricinehcl
ph
mm
mgso
mm
ethylenediaminetetraacet
acid
edta
mm
atp
mm
dithiothreitol
dtt
mm
luciferin
contain
triton
deterg
cell
incub
buffer
min
room
temperatur
luciferas
activ
measur
use
plate
luminomet
promega
evalu
impact
small
molecul
treatment
ebov
genom
replicationtranscript
step
plasmidbas
minigenom
assay
perform
plasmid
encod
ebov
minigenom
contain
firefli
luciferas
report
gene
provid
dr
elk
muhlberg
boston
univers
describ
previous
muhlberg
et
al
plasmid
encod
viru
shtanko
et
al
introduc
cell
plate
well
plate
use
transit
transfect
reagent
incub
overnight
cell
transfect
ng
ng
pcnp
ng
ng
ng
pcl
ng
plasmid
encod
polymeras
ng
plasmid
encod
renilla
luciferas
measur
transfect
effici
twentyfour
hour
transfect
cell
cultur
medium
chang
fresh
medium
contain
compound
cell
incub
addit
h
firefli
renilla
luciferas
activ
measur
use
dualluciferas
report
assay
system
promega
accord
manufactur
instruct
seri
structur
relat
amodiaquin
synthes
tabl
tabl
first
structur
featur
randomli
modifi
evalu
identifi
respons
improv
potenc
without
increas
toxic
compound
test
antivir
activ
use
replic
compet
ebov
encod
gfp
infect
report
cell
chosen
target
cell
sinc
deriv
human
liver
cell
one
major
target
ebov
infect
patholog
vivo
martin
et
al
consist
previou
report
use
cell
type
parent
compound
amodiaquin
inhibit
ebov
infect
inhibitori
concentr
ic
micromolar
rang
fig
current
work
cut
signific
improv
potenc
set
ic
correspond
amodiaquin
ic
minu
standard
deviat
sd
measur
fourteen
among
test
compound
show
improv
potenc
tabl
fig
highest
potenc
compound
ic
respect
cytotox
evalu
potent
compound
measur
cell
viabil
incub
done
infect
assay
accord
cytotox
concentr
cc
concentr
correspond
cell
cytotox
select
index
si
compound
calcul
divid
cc
ic
compar
amodiaquin
si
compound
yield
si
due
lower
cytotox
tabl
compound
also
gave
si
higher
amodiaquin
deriv
improv
potenc
low
toxic
chosen
lead
compound
derivat
initi
deriv
screen
reveal
improv
antiebov
potenc
gener
correspond
modif
alkyl
chain
extend
aminomethyl
group
r
tabl
seen
compound
extens
alkyl
chain
appear
increas
potenc
howev
presenc
tripl
coval
bond
compound
benzen
ring
compound
reduc
antivir
activ
amino
group
compound
hydroxyl
group
compound
impact
potenc
electroneg
halogen
bond
posit
quinolin
ring
r
appear
invers
correspond
potenc
fluorin
compound
highest
electroneg
produc
compound
lower
potenc
amodiaquin
chlorin
posit
contrast
bromin
compound
iodin
compound
lower
electroneg
improv
potenc
respect
tabl
phenol
ring
adduct
r
chlorobenzen
posit
effect
antivir
activ
highlight
higher
antivir
activ
compound
amodiaquin
tabl
compound
phenyl
ring
benzen
ring
attach
quinolin
ring
posit
r
compound
methoxi
group
also
show
higher
potenc
ebov
infect
tabl
result
deriv
consist
seen
quinacrin
also
phenyl
group
antimalari
agent
show
signific
antiebov
activ
ekin
et
al
contrast
compound
lack
structur
aminoquinolin
phenyl
ring
benzen
ring
bridg
amino
group
show
much
lower
potenc
amodiaquin
seen
compound
tabl
suggest
structur
core
critic
antiebov
activ
howev
amino
group
substitut
origin
secondari
amin
tertiari
amin
compound
show
similar
potenc
parent
amodiaquin
tabl
sar
initi
deriv
set
demonstr
alkyl
chain
moieti
extend
aminomethyl
group
halogen
bond
quinolin
ring
import
featur
improv
potenc
ebov
without
increas
cytotox
importantli
featur
independ
modifi
consequ
second
set
deriv
synthes
iodin
substitut
posit
quinolin
ring
combin
varieti
alkyl
chain
length
h
cell
fix
nuclei
stain
hoescht
imag
captur
microscopi
imag
cell
treat
compound
untreat
cell
shown
left
panel
infect
cell
express
gfp
total
cell
number
count
calcul
infect
normal
untreat
control
obtain
rel
infect
plot
function
compound
concentr
draw
doserespons
curv
right
panel
measur
perform
least
triplic
shown
mean
sd
similar
result
obtain
replic
experi
deriv
effici
block
ebov
infect
sever
show
higher
potenc
compound
alkyl
chain
amodiaquin
fig
consist
initi
screen
result
extens
alkyl
chain
posit
effect
antivir
activ
potent
compound
longest
chain
length
tabl
cytotox
test
reveal
compound
show
low
toxic
yield
si
higher
initi
deriv
set
therefor
appear
higher
potenti
treatment
ebola
viru
diseas
order
investig
potent
compound
affect
ebov
replic
cycl
test
host
cell
entri
viru
genom
replic
use
pseudotyp
viru
minigenom
assay
respect
shown
fig
c
infect
vesicular
stomat
viru
vsv
bear
ebov
glycoprotein
inhibit
compound
time
potent
vsv
bear
nativ
vsv
glycoprotein
potenc
compound
similar
within
ebovgfp
tabl
fig
contrast
activ
ebov
minigenom
significantli
affect
compound
wherea
mycophenol
acid
known
ebov
genom
replic
inhibitor
effect
block
signal
minigenom
fig
edward
et
al
result
indic
deriv
specif
block
host
cell
entri
ebov
moreov
compound
inhibit
entri
effici
amodiaquin
consist
outcom
ebovgfp
infect
fig
compound
repres
deriv
one
import
structur
featur
reveal
initi
screen
therefor
modif
improv
antivir
potenc
compound
specif
target
host
cell
entri
without
gain
antirepl
effect
work
confirm
amodiaquin
welltoler
drug
long
histori
use
treatment
malaria
also
antiebov
activ
importantli
possibl
modifi
compound
improv
potenc
altern
use
clear
sar
found
antiebov
activ
modif
enhanc
antivir
effect
appear
act
independ
import
featur
length
alkyl
chain
extend
aminomethyl
group
electroneg
halogen
bound
quinolin
ring
featur
combin
improv
potenc
toward
submicromolar
rang
achiev
addit
improv
potenc
mani
compound
better
toler
cultur
cell
amodiaquin
consequ
identifi
multipl
compound
show
much
higher
select
index
amodiaquin
amodiaquin
deriv
lead
compound
medicin
chemistri
develop
use
clinic
derivat
one
tradit
effect
techniqu
drug
develop
modifi
specif
structur
compon
approach
enhanc
specif
effect
reduc
toxic
improv
pharmacokinet
parent
drug
without
diminish
desir
featur
derivat
artemisinin
antimalari
drug
gener
effect
drug
artesun
improv
bioavail
balint
brincidofovir
promis
experiment
drug
dna
virus
deriv
antiherp
viru
cidofovir
much
higher
activ
poxvirus
potenti
antiebov
activ
well
lower
toxic
parker
et
al
olson
et
al
mcmullan
et
al
interestingli
brincidofovir
lengthen
alkyl
chain
structur
featur
potent
deriv
similar
parent
drug
case
tabl
chemic
structur
seri
amodiaquin
deriv
antivir
activ
ebovgfp
sakurai
et
al
antivir
research
amodiaquin
histori
medic
clinic
also
show
small
signific
clinic
benefit
patient
infect
ebov
gignoux
et
al
therefor
derivat
amodiaquin
appear
reason
process
order
discov
promis
therapeut
ebola
viru
diseas
result
demonstr
approach
potenti
work
diseas
indic
sar
analys
demonstr
alkyl
chain
extend
aminomethyl
group
one
key
modif
target
increas
antiebov
activ
modif
report
assist
drug
accumul
vacuolar
compart
parhizgar
tahghighi
suggest
effici
appropri
local
amodiaquin
deriv
infect
cell
import
factor
antiebov
activ
inde
amodiaquin
chloroquin
mammalian
cell
accumul
much
less
malaria
parasit
hawley
et
al
desir
properti
antimalari
use
antivir
consequ
antivir
potenc
much
less
report
antimalari
activ
ic
ten
nanomolar
rang
oneil
et
al
hocart
et
al
howev
studi
show
extens
alkyl
chain
amodiaquin
could
improv
antiebov
potenc
suggest
modif
appear
improv
efficaci
compound
accumul
host
mammalian
cell
addit
alkyl
chain
amodiaquin
import
vivo
drug
kinet
target
metabol
member
cytochrom
superfamili
potenti
affect
circul
halfliv
compound
kinet
insid
cell
backman
et
al
although
metabol
may
critic
amodiaquin
major
metabolit
desethylamodiaquin
still
similar
antiebov
activ
metabol
form
deriv
antivir
potenc
unknown
need
investig
moreov
amodiaquin
induc
rare
seriou
liver
injuri
suggest
caus
drug
metabol
modif
may
also
affect
toxic
deriv
vivo
need
verif
shimizu
et
al
deriv
screen
also
demonstr
substitut
halogen
bond
quinolin
ring
could
enhanc
antivir
potenc
halogen
substitut
insert
commonli
use
techniqu
drug
develop
hernand
et
al
modif
gener
affect
interact
compound
target
mechan
steric
effect
format
halogen
bond
strength
proport
electroneg
halogen
interestingli
sar
analysi
reveal
electroneg
halogen
invers
correspond
antiebov
potenc
suggest
effect
halogen
substitut
seem
depend
steric
effect
larger
halogen
could
effici
occupi
space
target
although
inhibitori
mechan
fig
amodiaquin
deriv
inhibit
glycoproteindepend
entri
ebov
address
effect
compound
viru
entri
cell
pseudotyp
virus
bear
glycoprotein
ebov
b
vsv
encod
firefli
luciferas
report
use
cell
treat
indic
dose
compound
challeng
either
pseudotyp
viru
luciferas
activ
measur
normal
untreat
control
mean
sd
n
data
set
repres
two
independ
experi
c
comparison
activ
amodiaquin
compound
compound
inhibit
pseudotyp
viru
infect
calcul
ic
valu
shown
mean
sd
independ
experi
perform
use
triplic
sampl
assess
ebov
transcript
replic
cell
transfect
plasmid
express
ebov
minigenom
rna
encod
firefli
luciferas
report
plasmid
express
compon
ebov
polymeras
complex
plasmid
express
renilla
luciferas
report
twentyfour
hour
later
cell
treat
dmso
untreat
amodiaquin
compound
compound
mycophenol
acid
posit
control
luciferas
activ
measur
addit
h
firefli
luciferas
activ
normal
renilla
luciferas
activ
shown
mean
sd
n
data
set
repres
two
independ
experi
amodiaquin
unclear
data
suggest
antiebov
effect
amodiaquin
appear
molecular
target
import
ebov
infect
accumul
cell
compart
requir
ebov
access
moreov
mechanist
assay
indic
molecular
target
compart
specif
ebov
entri
step
vsv
entri
compar
resist
compound
treatment
halogen
substitut
must
affect
physic
interact
amodiaquinederiv
target
amodiaquin
origin
develop
wide
use
clinic
offici
sinc
treatment
prophylaxi
malaria
howev
later
studi
reveal
activ
wide
rang
human
pathogen
includ
multipl
virus
flavivirus
coronavirus
alphavirus
bunyavirus
filovirus
boonyasuppayakorn
et
al
baba
et
al
han
et
al
moreov
inhibit
deliveri
anthrax
toxin
diphtheria
toxin
cytoplasm
well
growth
fungu
penicillium
marneffei
insid
macrophag
zilbermintz
et
al
taramelli
et
al
although
use
amodiaquin
pathogen
clinic
practic
due
weak
potenc
lead
candid
creat
potent
compound
exemplifi
studi
ebola
viru
moreov
multipl
amodiaquin
deriv
synthes
previous
shown
activ
pathogen
boonyasuppayakorn
et
al
baba
et
al
de
et
al
besid
origin
medic
purpos
antimalari
amodiaquin
may
anoth
potenti
lead
compound
develop
therapeut
agent
wide
rang
human
pathogen
